Veterinary-grade diazinon solution is a non-aqueous liquid concentrate supplied as an active pharmaceutical ingredient for further manufacture of ectoparasiticide and endectocide dosage forms, including tablets, injections, capsules, powders, granules, premixes, and topical solutions. The active substance is O,O-diethyl O-[6-methyl-2-(1-methylethyl)-4-pyrimidinyl] phosphorothioate, CAS 333-41-5, with a molecular weight of 304.35 g·mol⁻¹. The product is typically standardised to 60% w/w diazinon in a high-flash aromatic hydrocarbon solvent; alternative strengths require explicit label-claim adjustment. No harmonised model code exists; the material is ordered by CAS registry number, declared strength, and solvent system. Because the active substance is a liquid at ambient temperature, the solution form reduces airborne dust during weighing and permits closed-transfer operations. However, the solvent carrier imposes constraints on direct compression, aqueous granulation, and sterile filtration that are not present with crystalline organophosphate powders. The material is not intended for direct administration without dilution or incorporation into a registered veterinary medicinal product. Release documentation includes identity, assay, water content, residual solvent profile, acidity/alkalinity, and elemental impurities; batch-specific certificates of analysis should be reviewed before use.

Because the solution is highly concentrated, closed transfer and local exhaust ventilation are required during decanting and spray application. Polytetrafluoroethylene or stainless steel transfer lines are used to avoid swelling of polyvinyl chloride tubing by the aromatic solvent. Two batches with the same active content may differ in solvent evaporation behaviour and granule drying time; therefore, the solvent identity and boiling range are reviewed before each campaign. The solution is standardised gravimetrically, not volumetrically, because solvent density changes with temperature and water uptake.

Why is solvent composition the main release-risk factor for this liquid API?

The solvent system determines flash point, evaporation rate during granulation, residual solvent burden in dried intermediates, and compatibility with packaging elastomers. Aromatic hydrocarbon solvents with a boiling range above 180°C are common because they provide sufficient flash point for non-refrigerated warehousing and dissolve the active substance without increasing water content. Batch-to-batch differences in solvent composition can alter assay values when the active concentration is confirmed by volume rather than gravimetrically; therefore, standardisation is performed on a weight/weight basis. The solution is controlled for water content because diazinon undergoes hydrolytic degradation in the presence of free moisture, with degradation rate increasing as pH rises above 7.0 and as temperature is raised above 40°C. The residual solvent panel is matched to the declared solvent system and evaluated against VICH GL18 limits, with headspace gas chromatography used to resolve benzene, toluene, ethylbenzene, and xylene isomers. The flash point of the final solution is solvent-dependent and is reported in the batch-specific Safety Data Sheet rather than derived from the active substance alone. Viscosity and density are measured for pump-assisted transfer; a density near 1.02–1.07 g/cm³ at 20°C is typical for the 60% w/w concentrate, depending on the aromatic solvent cut.

For tablet and capsule manufacture, the liquid concentrate is not added directly to a final compression blend. The preferred route is adsorption onto a porous carrier such as microcrystalline cellulose, colloidal silicon dioxide, or maltodextrin in a high-shear mixer or top-spray fluid bed. The carrier is pre-dried to a loss on drying below 2.0% w/w before spraying; inlet air temperature is maintained below 60°C to limit oxidative degradation of the phosphorothioate. The adsorbate is passed through a 0.850 mm sieve and blended with disintegrant and lubricant to a target blend uniformity of not more than 5.0% RSD for the active fraction. Capsule filling with the same adsorbate is feasible if the bulk density is adjusted to 0.45–0.65 g/cm³ and the powder is protected from humidity above 60% RH. In direct compression, the liquid form is unsuitable, and the adsorbed intermediate behaves as a moisture-sensitive granule that requires moisture-barrier packaging. When continuous twin-screw granulation is used, the liquid feed rate is limited by the carrier’s absorptive capacity; overwetting produces agglomerates that segregate during transfer and reduce assay uniformity.

Drying of the adsorbed granule is the most sensitive step for solid oral intermediates. A fluid-bed dryer is operated with an inlet air dew point below 10°C and an exhaust temperature not exceeding 45°C; residual moisture is targeted at 1.0–2.5% w/w for direct compression and 0.5–1.5% w/w for moisture-sensitive capsule formulations. High exhaust temperatures above 50°C increase the loss of active due to volatilisation and oxidative degradation. The dried granule is screened before lubrication, and oversized fractions above 1.00 mm are milled with a low-shear rotor to avoid heat generation.

When aqueous dilution is required for spray, dip, or backrub application, the concentrated solution must be added slowly to buffered water, not the reverse. The working dilution is maintained at pH 4.0–6.0 because alkaline hydrolysis accelerates deactivation. Final active concentrations are determined by the authorised label and are typically below 1.0% w/v. Published data for half-life values under field conditions are limited and vary with source water hardness, temperature, and ultraviolet exposure; formulators should generate product-specific stability data for extended holding periods. Handling requires closed transfer, impermeable gloves, and cholinesterase monitoring for workers because the active substance is an organophosphate acetylcholinesterase inhibitor. Calcium hypochlorite and strong oxidising agents are incompatible with the diluted solution and should not be used for cleaning mixing vessels unless hydrolysed residues are separately validated.

Identity, assay, and residual solvent release limits for premix-grade material

The release panel for the 60% w/w solution is designed to confirm identity, active content, and solvent quality before the material is converted into solid dosage intermediates. The table lists the core release attributes; additional tests for density, viscosity, and flash point are included when the receiving site uses pump-assisted transfer or heated dosing equipment. All results are reported against the batch-specific label claim and the registered specification in the applicant’s dossier.

The assay method uses capillary gas chromatography with flame-ionisation detection and an internal standard; system suitability is confirmed as described in USP <621>. For residual solvent analysis, the sample is diluted in dimethyl sulfoxide and heated to 80°C before headspace injection. The water content method is Karl Fischer titration because the high solvent content interferes with loss-on-drying. The acidity/alkalinity value is monitored because acidic or basic impurities can accelerate hydrolysis of the phosphorothioate ester during storage.

Relative to coumaphos and phoxim, diazinon solution differs in physical state and formulation behaviour. Coumaphos is a solid at 20°C, which simplifies dry blending and tablet compression but requires milling to achieve adequate blend uniformity. Phoxim has a lower molecular weight and is often supplied as a liquid or low-melting solid, which can create dosing-line blockage if not temperature-controlled. Diazinon is a liquid at 20°C and has a log P value near 3.81, which favours penetration into lipophilic matrices such as polyvinyl chloride ear tags and oil-based pour-on formulations. The liquid solution, however, cannot be incorporated into a conventional dry granulation line without an adsorption step, whereas coumaphos and phoxim solids can be milled and dry-mixed. This is the primary process difference when selecting among organophosphate APIs for solid dosage forms.

When sterile filtration or terminal sterilisation is contemplated for injectable-grade material

The aromatic solvent system used in the concentrate is not suitable for direct parenteral administration and must be replaced with a parenteral solvent such as propylene glycol, glycerol formal, or low-molecular-weight polyethylene glycol under aseptic conditions. The active substance is susceptible to hydrolysis during terminal moist-heat sterilisation at 121°C, so aseptic filtration through a 0.22 µm membrane is preferred where a sterile dosage form is authorised. Filter compatibility with the selected solvent system must be confirmed because polyethersulfone and some nylon membranes exhibit extractable shifts in the presence of phthalate-free plasticisers. The pH of the finished injection is maintained between 4.0 and 6.0, and the solution is purged with nitrogen to reduce oxidative degradation. Published data for injectable diazinon formulations in target species are limited, and the compound’s narrow therapeutic index requires that any injectable use be justified by the approved risk assessment. The solvent-exchange step should be validated for residual aromatic solvent content because incomplete evaporation during solvent replacement may carry over into the finished injection above the permitted daily exposure.

In premix and feed-additive processing, dosing uniformity is determined at the intermediate level before final dilution with feed. The liquid concentrate is first adsorbed onto a carrier or spray-dried, then combined with ground corn, rice hulls, or lactose in a ribbon blender or paddle mixer. Blend uniformity for the active fraction is targeted at not more than 5.0% RSD, with sampling at 10 locations across the mixer. Carriers containing high free-ash or alkaline minerals should be avoided because localised pH elevation can accelerate hydrolysis at particle surfaces. The premix is packaged in moisture-barrier bags and labelled with a re-test date; opened containers are used within the shortest practical interval because ambient humidity above 60% RH increases water uptake and deactivation.

A validated premix line includes a final sieve and metal detection step, because foreign particulate from worn mixer blades can concentrate in high-density granules. In feed-mill trials, the dilution factor from intermediate premix to complete feed is typically 1:100 to 1:1000; the final mix is sampled at the mixer discharge to confirm that the active content remains within ±10% of label. When the premix is intended for free-choice mineral supplements, segregation during transport is reduced by maintaining a free-fat content below 2.0% w/w and by adding 0.5% w/w of a fumed silica anticaking agent.

Container closure integrity determines shelf-life predictability

The concentrate is filled into fluorinated HDPE or epoxy-phenolic lined steel containers under a nitrogen overlay to limit oxidative and hydrolytic degradation. Storage is at 15–25°C, protected from light and from ignition sources. Repeated opening of the container introduces humidity; therefore, transfer systems that permit closed-loop dispensing are preferred. Freezing is avoided because crystallisation of the active substance from the solvent can alter the concentration of the remaining liquid and produce variable dosing. The material should not be stored in containers made of uncoated mild steel or copper alloys, because trace metal ions can catalyse phosphorothioate degradation. Incompatible materials include strong oxidising agents, alkaline detergents, and unlined elastomers that absorb the aromatic solvent.